Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucose Monitoring

EXCLUSIVE: FENIX Interview with CGM Newcomer Allez Health (Part 1)

Here is a brief preview of this blast: To kick off the ADA 2024 conference, FENIX sat down with Leif Bowman, the co-founder of Allez Health, for an in-depth interview on the company’s goal to disrupt the CGM market. Recall, in May 2024, Allez announced it secured $60M in a Series A+ financing round led by Osang Healthcare Co. Ltd and with participation from existing investors (previous FENIX insight). For context, Allez (formerly called Zense-Life; view website) is an emerging biosensor venture founded by veterans in the CGM space. Below, FENIX provides Part 1 of our exclusive interview which includes insight into Allez’s business philosophy as well as an early look into the features of its CGM.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.